Skip to main content

Table 2 Univariate analysis for the association between clinical characteristics and survival in all and landmark groups with metastatic colon cancer received mFOLFOX6 as first-line treatment

From: Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients

 

All patients

Landmark patients

PFS

OS

PFS

OS

N (%)

Survival (months)

Median (95%CI)

P value

Survival (months)

Median (95%CI)

P value

N (%)

Survival (months)

Median (95%CI)

P value

Survival (months)

Median (95%CI)

P value

KPS

 90

273 (94)

5.9 (5.1–6.9)

0.287

17.5 (8.1–22.8)

0.371

218 (94)

6.3 (5.6–6.9)

0.154

17.8 (17.1–23.9)

0.071

 70–80

17 (6)

2.7 (2.6–2.9)

 

15.4 (9.8–18.9)

 

14 (6)

2.8 (2.6–3.7)

 

15.6 (10.9–20.9)

 

Pathological differentiation

 Well-moderate

229 (79)

5.7 (4.6–6.8)

0.053

12.6 (11.6–13.7)

0.060

187 (80)

6.3 (5.2–7.4)

0.785

13.7 (10.9–16.6)

0.040

 poor

61 (21)

5.3 (2.7–7.9)

 

10.2 (5.9–14.7)

 

45 (20)

6.2 (4.8–7.7)

 

12.0 (8.1–15.9)

 

Liver metastasis

 presence

222 (76)

4.9 (4.0–5.9)

0.116

12.1 (10.7–13.6)

0.282

178 (77)

5.9 (4.9–6.9)

0.195

12.0 (8.1–15.9)

0.132

 absence

68 (24)

6.9 (6.3–7.5)

 

16.3 (10.5–21.4)

 

54 (23)

6.2 (4.8–7.7)

 

12.8 (11.4–14.1)

 

Severity of CIN

 Mild

132 (46)

6.9 (5.9–7.8)

<0.001

16.3 (13.4–19.2)

<0.001

120 (52)

6.9 (6.1–7.9)

<0.001

18.1 (13.6–22.4)

<0.001

 Severe

49 (17)

7.2 (5.7–8.7)

 

16.1 (7.3–25.1)

 

42 (18)

7.6 (6.0–7.9)

 

18.8 (11.0–26.7)

 

 Absence

109 (37)

3.2 (2.6–3.8)

 

6.7 (5.4–7.9)

 

70 (30)

3.4 (2.7–4.1)

 

9.5 (8.0–10.9)

 

 M vs. A

  

<0.001

 

<0.001

  

<0.001

 

<0.001

 L vs. A

  

<0.001

 

<0.001

  

<0.001

 

<0.001

 M vs. L

  

0.416

 

0.139

  

0.360

 

0.127

Timing of CIN

 Early-onset

141 (49)

7.2 (6.4–8.0)

<0.001

20.7 (16.1–25.4)

<0.001

130 (56)

7.7 (6.5–8.9)

<0.001

21.9 (18.5–25.7)

<0.001

 Late-onset

40 (14)

6.2 (5.9–6.6)

 

12.8 (11.6–13.9)

 

32 (14)

6.3 (5.9–6.6)

 

13.3 (11.9–14.7)

 

 Absence

109 (37)

3.2 (2.7–3.8)

 

6.7 (5.6–7.8)

 

70 (30)

3.4 (2.7–4.1)

 

9.5 (7.9–10.9)

 

 E vs. A

  

<0.001

 

<0.001

  

<0.001

 

<0.001

 L vs. A

  

<0.001

 

<0.001

  

0.003

 

0.009

 E vs. L

  

0.115

 

<0.001

  

0.095

 

<0.001

  1. Abbreviation CIN chemotherapy-induced neutropenia, M mild CIN, S severe CIN, A absence of CIN, E early-onset CIN, L late-onset CIN
  2. A two-sided significance level of 0.05 was used to evaluate statistical significance